Education
About Us
Working with TipRanks
Follow Us
Alterity Therapeutics (ATHE)
:ATHE
ATHE Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.00 - $5.87
Previous CloseN/A
Volume131.33K
Average Volume (3M)21.94K
Market Cap
$45.90M
Enterprise Value$2.03M
Total Cash (Recent Filing)AU$2.88M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta1.19
Next Earnings
Feb 26, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.58
Shares Outstanding15,212,284
10 Day Avg. Volume25,677
30 Day Avg. Volume21,939
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$8.00Price Target Upside154.78% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Alterity Therapeutics News
PremiumCompany Announcements
Alterity Therapeutics Completes Key Phase 2 Trial for MSA Treatment
PremiumCompany Announcements
Alterity Therapeutics Reports Progress and Financial Results
PremiumCompany Announcements
Alterity Therapeutics Announces Change in Substantial Holding
PremiumCompany Announcements
Alterity Therapeutics Expands Capital with New Securities Quotation---
Bulls Say, Bears Say
Bulls Say
Clinical ResultsAlterity Therapeutics reported positive clinical results for its Phase 2 trial of ATH434 in Multiple System Atrophy, including 48% slowing of clinical progression at the 50 mg dose level.
Financial PerformanceAlterity announced it raised A$40M (~$24.8M in USD) through a two-tranche placement of its fully paid ordinary shares.
Regulatory EngagementBased on the Phase 2 results, Alterity intends to engage the FDA to discuss next steps in the development of ATH434 in MSA, a disease with a small patient population but few treatment options.
Bears Say
Stock RecommendationThe recommendation on ATHE shares is being lowered to Hold as these shares have exceeded the $4 price target.
---
Ownership Overview
―
Insiders
0.01% Mutual Funds
0.34% Other Institutional Investors
99.65% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
ATHE FAQ
What was Alterity Therapeutics’s price range in the past 12 months?
Alterity Therapeutics lowest stock price was $1.00 and its highest was $5.87 in the past 12 months.
What is Alterity Therapeutics’s market cap?
Alterity Therapeutics’s market cap is $45.90M.
When is Alterity Therapeutics’s upcoming earnings report date?
Alterity Therapeutics’s upcoming earnings report date is Feb 26, 2026 which is in 319 days.
How were Alterity Therapeutics’s earnings last quarter?
Alterity Therapeutics released its earnings results on Feb 28, 2025. The company reported -$0.435 earnings per share for the quarter, missing the consensus estimate of -$0.136 by -$0.299.
Is Alterity Therapeutics overvalued?
According to Wall Street analysts Alterity Therapeutics’s price is currently Undervalued.
Does Alterity Therapeutics pay dividends?
Alterity Therapeutics does not currently pay dividends.
What is Alterity Therapeutics’s EPS estimate?
Alterity Therapeutics’s EPS estimate is -0.14.
How many shares outstanding does Alterity Therapeutics have?
Alterity Therapeutics has 15,212,284 shares outstanding.
What happened to Alterity Therapeutics’s price movement after its last earnings report?
Alterity Therapeutics reported an EPS of -$0.435 in its last earnings report, missing expectations of -$0.136. Following the earnings report the stock price went down -2.326%.
Which hedge fund is a major shareholder of Alterity Therapeutics?
Currently, no hedge funds are holding shares in ATHE
---
Alterity Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.00 (154.78% Upside)
$8.00 (154.78% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
19.20%
12-Months-Change
Fundamentals
Return on Equity
-154.88%
Trailing 12-Months
Asset Growth
-56.88%
Trailing 12-Months
Company Description
Alterity Therapeutics
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase IIa clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.
---
ATHE Stock 12 Month Forecast
Average Price Target
$8.00
▲(154.78% Upside)
Technical Analysis
Best Analysts Covering ATHE
1 Year
1 Year Success Rate
2/3 ratings generated profit
1 Year Average Return
+5.43%
reiterated a buy rating 3 days ago
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +5.43% per trade.
---